Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03605745 · ClinicalTrials.gov registry record · NA
Minimally Invasive Prostatic Vapor Ablation for the Treatment of BPH in Large Prostates (Rezūm XL)
A NA study, sponsored by Boston Scientific Corporation.
- Terminated
- Registry status
- NA
- Development phase
- 47
- Enrollment target
NCT03605745 is a NA study that was terminated before completion, run by Boston Scientific Corporation. The registered enrollment target is 47 participants.
The verdict
NCT03605745, a NA study, was terminated before completion, sponsored by Boston Scientific Corporation.
- TERMINATED
- Registry status
- NA
- Development phase
- 47 participants
- Enrollment target
Study Summary
Prospective, multicenter, single arm clinical trial designed to evaluate the safety of the Rezūm System in treating subjects with symptomatic BPH for prostate sizes \>80cm3 and ≤150 cm3.
Interventions
- DEVICE Prostatic Vapor Ablation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2018-06-19 |
| Est. Completion | 2020-08-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03605745
The ClinicalTrials.gov registry entry for NCT03605745 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Prostatic Vapor Ablation is the first listed.
NCT03605745 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03605745 about?
NCT03605745 is a clinical study titled "Minimally Invasive Prostatic Vapor Ablation for the Treatment of BPH in Large Prostates (Rezūm XL)". Prospective, multicenter, single arm clinical trial designed to evaluate the safety of the Rezūm System in treating subjects with symptomatic BPH for prostate sizes \>80cm3 and ≤150 cm3.
What is the current status of trial NCT03605745?
This trial is currently terminated. It is a NA study. The enrollment target is 47 participants. The study started on 2018-06-19. Estimated completion is 2020-08-11.
What interventions are being tested in trial NCT03605745?
The interventions under investigation include: Prostatic Vapor Ablation (DEVICE).
Who is sponsoring clinical trial NCT03605745?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.